LIAISON PLEX® Gram-Negative Blood Culture Assay
Optimize Treatment in Hours—Not Days
The LIAISON PLEX® Gram-Negative Blood Culture Assay integrates with your standard-of-care workflow for maximum clinical impact through the molecular detection and differentiation of 27 targets including 19 gram-negative bacteria frequently found to cause bacteremia, plus 8 resistance genes associated with these bacteria.
Powered by Bioz
Disease state
Sepsis is the leading cause of mortality in US hospitals, with over 1.7 million cases diagnosed annually.1 Delays in optimal treatment significantly increase the risk of mortality, with estimates indicating a 7.6% rise in fatality rates for each hour of delay.2 The financial burden of acute sepsis hospitalization is substantial, with annual costs estimated at $62 billion.3
Gram-negative bacteremia accounts for approximately 30% of all positive blood cultures. Invasive gram-negative bacteremia often requires therapeutic adjustments from more generalized empiric therapy.4
1. http://dx.doi.org/10.15585/mmwr.mm7234a2
2. https://doi.org/10.3390/antibiotics11091202
3. https://www.sepsis.org/education/resources/fact-sheets/
4. https://pubmed.ncbi.nlm.nih.gov/16107985/
Sepsis is a disease associated with high mortality.
The value of LIAISON PLEX® Gram-Negative Blood Culture Assay
Empower clinicians to rapidly optimize treatment for gram-negative bacteremia.
Clinical impact
Comprehensive pathogen and resistance gene coverage enhances diagnostic accuracy, empowering informed decisions to optimize patient management while also reinforcing antimicrobial stewardship—ultimately aiding in the fight against bloodstream infections and sepsis.
Outstanding economic value
Designed for seamless workflow integration, the Gram stain-based panel selection enhances diagnostic stewardship while optimizing operational costs.
The right assay design
Non-amplified molecular chemistry helps minimize false results that may occur with PCR-based amplification of non-viable DNA in blood culture media.
How the LIAISON PLEX® Gram-Negative Blood Culture Assay works
LIAISON PLEX® Gram-Negative Blood Culture Assay is a syndromic in vitro diagnostic test for the detection and identification of invasive pathogenic gram-negative bacteria from positive culture samples. Subculturing is necessary for the identification and susceptibility testing of organisms not detected by the assay, in conjunction with standard of care culture workflows.
Transfer sample
Transfer sample to cartridge.
Scan
Scan the Sample ID and the Cartridge ID.
Load and run
Load the cartridge, initiate the Run, and walk away.
LIAISON PLEX® Gram-Negative Blood Culture (BCN) Assay
Gram-Negative Bacteria |
|
Resistance Genes |
|---|---|---|
| Acinetobacter baumannii |
Klebsiella variicola |
CTX-M (blaCTX-M) |
| Acinetobacter spp. |
Morganella morganii |
IMP (blaIMP) |
| Citrobacter spp. |
Neisseria meningitidis |
KPC (blaKPC) |
| Enterobacter spp. |
Proteus spp. |
NDM (blaNDM) |
| Enterobacteriaceae/Morganellaceae |
Pseudomonas aeruginosa |
OXA (blaOXA) |
| Escherichia coli |
Pseudomonas spp. |
SME (blaSME) |
| Haemophilus influenzae |
Salmonella spp. |
VIM (blaVIM) |
| Klebsiella oxytoca |
Serratia marcescens |
MCR |
| Klebsiella pneumoniae |
Stenotrophomonas maltophilia |
To be used on the LIAISON PLEX® System
The LIAISON PLEX® System is a next-generation, multiplex, sample-to-answer molecular diagnostic platform. Designed to support both PCR and non-amplified assays, offering the most optimal testing approach for each patient, ensuring precise and personalized diagnostics.
LIAISON PLEX®
Flexibility like never before with an easy-to-use, automated system for customizable syndromic testing.
LIAISON PLEX® Gram-Negative Blood Culture Assay ordering info
Part Name |
Kit Size |
Registration Status |
Part Number |
|---|---|---|---|
|
LIAISON PLEX® Gram-Negative |
12 |
IVD |
20-005-303 |